Publicaciones en colaboración con investigadores/as de Westmead Hospital (22)

2024

  1. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

    Journal of Neurology, Neurosurgery and Psychiatry

2023

  1. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  2. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

  4. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

    Journal of Cystic Fibrosis, Vol. 21, Núm. 4, pp. e221-e231

  5. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

2020

  1. Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases

    European Respiratory Journal

  2. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

  3. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

    Journal of Cystic Fibrosis, Vol. 19, Núm. 6, pp. 868-871

  4. Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020

    Emerging Infectious Diseases, Vol. 26, Núm. 11, pp. 2709-2712

2019

  1. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468

2018

  1. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

    Multiple Sclerosis and Related Disorders, Vol. 19, pp. 105-108

  2. Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 24, Núm. 12, pp. 1569-1577

2017

  1. Contribution of different relapse phenotypes to disability in multiple sclerosis

    Multiple Sclerosis, Vol. 23, Núm. 2, pp. 266-276

  2. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

    Brain, Vol. 140, Núm. 9, pp. 2426-2443

  3. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

    The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281

2016

  1. Defining secondary progressive multiple sclerosis

    Brain, Vol. 139, Núm. 9, pp. 2395-2405